Production and Metabolism of Cytotoxic Phospholipids Generated during Incubation of Liposomes with Oxyhemoglobin

  • Keizo Inoue
  • Hiroyuki Itabe
  • Ichiro Kudo
Part of the Basic Life Sciences book series (BLSC, volume 49)


It is now widely accepted that liposomes are useful drug delivery systems. The encapsulation of a drug inside liposomes often decreases the toxicity of the drug while maintaining or enhancing its efficacy. Liposomal drugs have many applications including anticancer, antiviral, antibacterial, antifungal, and anti-inflammatory therapy. It is therefore increasingly necessary to develop liposomal formulations that satisfy pharmaceutical demands for safety and stability in vivo. Many investigations have been performed to prepare liposomes that are stable in buffer, ‘but little information has been available concerning the stability and safety of liposomes after injection into the human body. Since they are used mostly to treat diseases, liposomes must be safe and stable under pathological conditions.


Liposomal Drug Cytotoxic Product Liposomal Lipid Conjugate Diene Concentration Extracellular Phospholipase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M.J. Ostro, Liposomes, Scientific American 256:90 (1987).CrossRefGoogle Scholar
  2. 2.
    G. Poste, R. Kirsh and P. Bugelski, Liposomes as a drug delivery system in cancer therapy, in: “Novel approaches to cancer chemotherapy,” P.S. Sunkara, ed., Academic Press, Orlando (1984).Google Scholar
  3. 3.
    G. Gregoriadis, “Liposome technology,” vol. 1, Preparation of liposomes, CRC Press, Boca Raton (1984).Google Scholar
  4. 4.
    A.D. Bangham, “Liposome letters,” Academic Press, London (1983).Google Scholar
  5. 5.
    S.M. Grüner, R.P. Lenk, A.S. Janoff, and M.J. Ostro, Novel multilayered lipid vesicles: Comparison of physical characteristics of multilamellar liposomes and stable plurilamellar vesicles, Biochemistry 24:2833 (1985).PubMedCrossRefGoogle Scholar
  6. 6.
    E.M.G. van Bommel, D.J.A. Crommelin, Stability of doxorubicin-liposomes on storage: as an aqueous dispersion, frozen or freeze-dried, Int. J. Pharm. 22:277 (1984).Google Scholar
  7. 7.
    A.M. Michelson, Clinical use of superoxide dismutase and possible pharmacological approaches, in: “Pathology of oxygen,” Autor, A.P. ed., Academic Press, New York (1982).Google Scholar
  8. 8.
    J. Szebeni, and K. Toth, Lipid peroxidation in hemoglobin-containing Liposomes. Effects of membrane phospholipid composition and cholesterol content, Biochim. Biophys. Acta 857:139 (1986).CrossRefGoogle Scholar
  9. 9.
    M.B. Yatvin, W. Kreutz, B.A. Horwitz, and M. Shinitzky, pH-Sensitive liposomes: Possible clinical implications, Science 210:1253 (1980).PubMedCrossRefGoogle Scholar
  10. 10.
    J. Connor and L. Huang, Efficient cytoplasmic delivery of a fluorescent dye by pH-sensitive immunoliposomes, J. Cell Biol. 101:582 (1985).PubMedCrossRefGoogle Scholar
  11. 11.
    R.J.Y. Ho and L. Huang, Target-sensitive immunoliposomes: preparation and characterization, Biochemistry 25;5500 (1986).PubMedCrossRefGoogle Scholar
  12. 12.
    A.S. Janoff, S. Carpenter-Green, A.L. Weiner, J. Seibold, G. Weissmann, and M.J. Ostro, Novel liposome composition for a rapid colorimetric test for systemic lupus erythematosus, Clin. Chem. 29:1587 (1983).Google Scholar
  13. 13.
    D. Lavelle, M.J. Ostro, W. Paxton, D. Blaustein, and D. Giacomoni, Further studies on liposome-mediated RNA delivery into cells in vitro Arch. Biochem. Biophys. 215:486 (1982).CrossRefGoogle Scholar
  14. 14.
    F. Bonte and R.L. Juliano, Interactions of liposomes with serum proteins, Chem. Phys. Lipids 40:359 (1986).PubMedCrossRefGoogle Scholar
  15. 15.
    H.W. Chang, I. Kudo, S. Hara, K. Karasawa, and K. Inoue, Extracellular phospholipase A activity in peritoneal cavity of casein-treated rats, J. Biochem. 100:1099 (1986).PubMedGoogle Scholar
  16. 16.
    M. Tsujimoto, K. Inoue, and S. Nojima, Reactivity of human C-reactive protein with positively charged liposomes, J. Biochem. 90:1507 (1981).PubMedGoogle Scholar
  17. 17.
    T. Kobayashi, H. Itabe, K. Inoue, and S. Nojima, Peroxidation of liposomes in the presence of human erythrocytes and induction of membrane damage of erythrocytes by peroxidized liposomes, Biochim. Biophys. Acta 814:170 (1985).CrossRefGoogle Scholar
  18. 18.
    H. Itabe, T. Kobayashi, and K. Inoue, Generation of toxic phospholipid(s) during oxyhemoglobin-induced peroxidation of phosphatidylcholines, submitted for publication.Google Scholar
  19. 19.
    A. Benedetti, M. Comporti, and H. Esterbauer, Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids, Biochim. Biophys. Acta 620:281 (1980).CrossRefGoogle Scholar
  20. 20.
    H. Itabe, I. Kudo, Y. Kushi, S. Honda, and K. Inoue, Identification of a toxic phospholipid generated during oxyhemoglobin-induced peroxidation of phosphatidylcholine, in preparation.Google Scholar
  21. 21.
    H. Itabe, I. Kudo, and K. Inoue, Synthesis and characterization of 2-azelaoyl phosphatidylcholine, one of the toxic products of lipid peroxidation, in preparation.Google Scholar
  22. 22.
    H. Esterbauer, Aldehydic products of lipid peroxidation, in: “Free radicals, lipid peroxidation and cancer”, D.C.H. McBrien and T.F. Slater ed., Academic Press, London, (1982).Google Scholar
  23. 23.
    E.N. Frankel, Volatile lipid oxidation products, Prog. Lipid Res. 22:1 (1983).PubMedCrossRefGoogle Scholar
  24. 24.
    F.J.G.M. van Kujik, A. Sevanian, G.J. Handelman, and E.A. Dratz, A new role for phospholipase A2: Protection of membranes from lipid peroxidation damage, Trends Biochem. Soc. 12:31 (1987).CrossRefGoogle Scholar
  25. 25.
    A. Sevanian and E. Kim, Phosphlipase A dependent release of fatty acids from peroxidized membranes, J. Free Radicals Biol. Med. 1:263 (1985).CrossRefGoogle Scholar
  26. 26.
    F.J.G.M. van Kuijk, G.J. Handelman, and E.A. Dratz, Consecutive action of phospholipase A2 and glutathione peroxidase is required for reduction of phospholipid hydroperoxides and provides a convenient method to determine peroxide value in membrane, J. Free Radicals Biol. Med. 1:421 (1985).CrossRefGoogle Scholar
  27. 27.
    R. Franson, R. Dobrow, J. Weiss, P. Elsbach, and W.B. Weglicki, Isolation and characterization of phospholipase A from an inflamatory exudate, J. Lipid Res. 19:18 (1978).PubMedGoogle Scholar
  28. 28.
    T.J. Nevalainen, The role of phospholipase A in acute pancreatitis, Scan. J. Gastroent. 15:641 (1980).Google Scholar
  29. 29.
    E. Stefanski, W. Pruzauski, B. Sternby, and P. Vadas, Purification of a soluble phospholipase A from synovial fluid in rheumatoid arthritis, J. Biochem. 100:1297 (1986).PubMedGoogle Scholar
  30. 30.
    H.W. Chang, I. Kudo, M. Tomita, and K. Inoue, Purification and characterization of extracellular phospholipase A from peritoneal cavity of caseinate-treated rat, J. Biochem. 102:147 (1987).PubMedGoogle Scholar
  31. 31.
    H. Itabe, I. Kudo, and K. Inoue, “Peroxidized phospholipid specific” phospholipase A2 activity in peritoneal cavity of casein-treated rats, in preparation.Google Scholar
  32. 32.
    R.Y. Youngman, Oxygen activation: Is the hydroxyl radial always biologically relevant?, Trends Biochem. Soc. 9:280 (1984).CrossRefGoogle Scholar
  33. 33.
    B. Halliwell and J.M.C. Gutteridge, Iron and free radical reactions: Two aspects of antioxidant protection, Trends Biochem. Soc. 11:372 (1986).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Keizo Inoue
    • 1
  • Hiroyuki Itabe
    • 1
  • Ichiro Kudo
    • 1
  1. 1.Faculty of Pharmaceutical SciencesUniversity of TokyoHongo, TokyoJapan

Personalised recommendations